Home
Resources
Diseases
COVID-19
Ebola
Hepatitis B
Human papillomavirus (HPV)
Malaria
Measles
Mpox
Pneumococcal disease
RSV (Respiratory syncytial virus)
Compendium
Hepatitis B birth dose vaccines
Hexavalent vaccines
HPV vaccines
Malaria vaccines
PCV vaccines
RSV vaccines
TCV vaccines
Training
Vaccine Portfolio Optimization and Prioritization (VPOP)
Evaluation
The Tool
The Tutorial
The Dashboard
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Selected
SAGE documentation
Japanese encephalitis
Type of publications
NITAG documentation (16)
Reports (1)
SAGE documentation (10)
Systematic reviews (SYSVAC) (8)
Topics
GRADE table (9)
Position paper (1)
Diseases
Japanese encephalitis (10)
Cholera (5)
COVID-19 (34)
Dengue (13)
Diphtheria (4)
Ebola (7)
Haemophilus influenzae type B (4)
Hepatitis A (11)
Hepatitis B (4)
Hepatitis E (2)
Herpes zoster (2)
Human papillomavirus (HPV) (18)
Influenza (17)
Malaria (13)
Measles (14)
Meningococcal disease (7)
Mpox (7)
Mumps (2)
Pertussis (4)
Pneumococcal disease (12)
Poliomyelitis (20)
Rabies (5)
Rotavirus (1)
RSV (Respiratory syncytial virus) (4)
Rubella (8)
Smallpox (1)
Tetanus (2)
Tick-borne encephalitis (1)
Tuberculosis (9)
Typhoid (8)
Varicella (3)
Yellow fever (3)
Show more
Available to download in languages
fr (1)
10 results found
2015
∙
SAGE
What is the risk of serious adverse events following vaccination with live attenuated JE vaccine?
2015
∙
SAGE
What is the risk of serious adverse events following vaccination with live recombinant JE vaccine?
2015
∙
SAGE
Is there a need for a booster dose following immunization with one dose of live attenuated JE vaccine in individuals living in JE-endemic areas?
2015
∙
SAGE
Is there a need for a booster dose following immunization with a single dose of live recombinant JE vaccine in vaccinees living in JE-endemic areas?
2015
∙
SAGE
Is there a need for a booster dose following immunization with the primary series of inactivated Vero cell-derived JE vaccine in individuals living in JE-endemic areas?
2015
∙
SAGE
Japanese Encephalitis Vaccines: WHO position paper
2015
∙
SAGE
What is the effectiveness of inactivated Vero cell-derived JE vaccine in preventing JE disease in vaccinees living in JE-endemic areas?
2015
∙
SAGE
What is the effectiveness of live attenuated JE vaccine in preventing JE disease in vaccinees living in JE-endemic areas?
2015
∙
SAGE
What is the effectiveness of live recombinant JE vaccine in preventing JE disease in vaccinees living in JE-endemic areas?
2015
∙
SAGE
What is the risk of serious adverse events following vaccination with inactivated Vero cell-derived JE vaccine?
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register
